This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
== See also == Calorimeter Clinical chemistry Environmental chemistry Ion beam analysis List of chemical analysis methods Important publications in analytical chemistry List of materials analysis methods Measurement uncertainty Metrology Microanalysis Nuclear reaction analysis Quality of analytical results Radioanalytical chemistry Rutherford backscattering spectroscopy Sensory analysis - in the field of Food science Virtual instrumentation Working range
==== In calves ==== In one study involving young cattle measurable proxies for pain were identified. Such proxies included heart rate and the plasma concentrations of the stress hormones cortisol, epinephrine, norepinephrine and catecholamine. Heart rate was monitored with standard veterinary ECG equipment and hormone concentrations determined through repeated blood sampling. An increase in any of these stress hormones or vocalization by the animal was assumed to register an increase in pain. A small microphone taped to the calves' throat was used to capture their vocalization response. Twenty-seven calves were divided into three groups. Each group received either a hot-iron brand, a freeze brand using liquid nitrogen, or a "sham" brand. The sham brand was an iron kept at room temperature and pressed to the calves' skin for the same duration as a hot brand. The sham branding created a control group used to determine baseline levels of vocalization and normal hormone concentrations. A cannula was inserted into the jugular vein of each calf to sample their blood during branding. These cannula were inserted into each calf 14 to 20 hours before the experiment using squeeze chutes in a different building from the one in which they would be branded. To minimize systematic bias, researchers used blocking to separate the calves by temperament, weight, and sex. Random assignment was then used to determine the order in and the day on which a given animal was branded.
== Research directions == Key research questions in PMOS focus on the best way to manage the condition, including with new anti-obesity drugs. In terms of criteria for diagnosis, age-specific levels of AMH need to be specified. Biomarkers are needed for early diagnosis and to guide drug development. Another open question is how to define the male phenotype to assess male relatives of women with PMOS. Research is exploring better ways to assess and predict metabolic complications. Current clinical tests for insulin resistance lack accuracy and standardisation, and the gold-standard method is impractical in clinical settings. Emerging approaches include multiomics, which may uncover biomarkers for diagnosis and subtyping, and artificial intelligence (AI)-based methods, which can identify patterns in medical data and also classify patients into subgroups. Combining AI with omics might improve early diagnosis, risk prediction, personalised treatment, and long-term monitoring, though robust validation in large, diverse cohorts remains necessary. As of 2024, studies have successfully developed in vitro PMOS disease models through human embryonic stem cells (hESCs) and induced pluripotent stem cell technology (iPSC). Both can be derived from individuals with PMOS and can differentiate into various cell types. Using adult somatic cells, iPSCs can reprogram the cells into a pluripotent state, which can then be specified to replicate PMOS-like traits.
== Units and unit conversions == The serum concentration of prolactin can be given in mass concentration (μg/L or ng/mL), molar concentration (nmol/L or pmol/L), or international units (typically mIU/L). The current IU is calibrated against the third International Standard for Prolactin, IS 84/500. Reference ampoules of IS 84/500 contain "approximately" 2.5 μg of lyophilized human prolactin and have been assigned an activity of 0.053 International Units by calibrating against the previous standard. Measurements can be converted into mass units using this ratio of grams to IUs to obtain an equivalent in relationship to the contents of IS 84/500; prolactin concentrations expressed in mIU/L can be converted to μg/L of IS 84/500 equivalent by dividing by 21.2. Previous standards had other ratios in relation to their potency on the assay measurement. For example, the previous IS (83/562) had a potency of 27.0 mIU per μg. The first International Reference Preparation (or IRP) of human Prolactin for Immunoassay was established in 1978 (75/504 1st IRP for human prolactin) at a time when purified human prolactin was in short supply. Previous standards relied on prolactin from animal sources. Purified human prolactin was scarce, heterogeneous, unstable, and difficult to characterize. A preparation labeled 81/541 was distributed by the WHO Expert Committee on Biological Standardization without official status and given the assigned value of 50 mIU/ampoule based on an earlier collaborative study.
===== Efficacy ===== Sustained and significant improvement in FSFI scores throughout a 52-week extension was attained, indicating a high efficacy of the drug treating HSDD, most notably when anticipating the challenge in psychological distress.
Sources: en.wikipedia.org
==== Discoveries ==== The chemosynthetic communities of the Gulf of Mexico have been studied extensively since the 1990s, and communities first discovered on the upper slope are likely the best understood seep communities in the world. The history of the discovery of these remarkable animals has all occurred since the 1980s. Each major discovery was unexpected―from the first hydrothermal vent communities anywhere in the world to the first cold seep communities in the Gulf of Mexico. Communities were discovered in the eastern Gulf of Mexico in 1983 using the crewed submersible DSV Alvin, during a cruise investigating the bottom of the Florida Escarpment in areas of "cold" brine seepage, where they unexpectedly discovered tubeworms and mussels. Two groups fortuitously discovered chemosynthetic communities in the central Gulf of Mexico nearly concurrently in November and December 1984. During investigations in late December on the research vessel R/V Gyre cruise 84-G-12, by Texas A&M University, two bottom trawls were conducted to determine the effects of oil seepage on benthic ecology (until this investigation, all effects of oil seepage were assumed to be detrimental). Trawls unexpectedly recovered extensive collections of chemosynthetic organisms, including tubeworms and clams. a month earlier, LGL Ecological Research Associates was conducting a research cruise as part of the multiyear MMS Northern Gulf of Mexico Continental Slope Study (Gallaway et al., 1988).
One visit to Afghanistan, Angola, Argentina, Belarus, Benin, Cameroon, Canada, Chad, Chile, Colombia, Comoros, Cuba, Cyprus, Czech Republic, Democratic Republic of the Congo, Ethiopia, Georgia, Guinea, Haiti, Iceland, Indonesia, Ireland, Ivory Coast (Côte d'Ivoire), Kazakhstan, Laos, Latvia, Lithuania, Luxembourg, Madagascar, Malaysia, Monaco, Niger, Norway, Palestine, Peru, Philippines, Romania, Singapore, Slovenia, South Korea, Turkey, Ukraine, Uruguay and Vietnam. Two visits to Algeria, Armenia, Australia, Azerbaijan, Egypt, India, Iraq, Israel, Japan, Jordan, Lebanon, Mexico, Netherlands, Nigeria, Portugal, Qatar, Senegal, South Africa, United Arab Emirates and Vatican City. Three visits to Brazil, the Central African Republic, China, Greece, Mali, Morocco, Slovakia and Tunisia. Four visits to Malta and Switzerland. Five visits to Russia, Spain and Saudi Arabia. Six visits to Poland. Seven visits to the United Kingdom. Eight visits to Italy. Ten visits to the United States. Twenty-two visits to Germany. Forty-two visits to Belgium.
=== Appearance === Semen normally has a whitish-gray colour. It tends to get a yellowish tint as a man ages. Semen colour is also influenced by the food we eat: foods that are high in sulfur, such as garlic, may result in a man producing yellow semen. Presence of blood in semen (hematospermia) leads to a brownish or red coloured ejaculate. Hematospermia is a rare condition. Brown semen is a result of infection, inflammation, trauma or tumor in the urological components such as the urethra, epididymis and seminal vesicles Semen that has a deep yellow colour or is greenish in appearance may be due to medication.Other causes of unusual semen colour include sexually transmitted infections such as gonorrhea and chlamydia, genital surgery and injury to the male sex organs.
Oligonucleotide synthesis is the chemical synthesis of relatively short fragments of nucleic acids with defined chemical structure (sequence). The technique is extremely useful in current laboratory practice because it provides a rapid and inexpensive access to custom-made oligonucleotides of the desired sequence. Whereas enzymes synthesize DNA and RNA only in a 5' to 3' direction, chemical oligonucleotide synthesis does not have this limitation, although it is most often carried out in the opposite, 3' to 5' direction. Currently, the process is implemented as solid-phase synthesis using phosphoramidite method and phosphoramidite building blocks derived from protected 2'-deoxynucleosides (dA, dC, dG, and T), ribonucleosides (A, C, G, and U), or chemically modified nucleosides, e.g. LNA or BNA. To obtain the desired oligonucleotide, the building blocks are sequentially coupled to the growing oligonucleotide chain in the order required by the sequence of the product (see Synthetic cycle below). The process has been fully automated since the late 1970s. Upon the completion of the chain assembly, the product is released from the solid phase to solution, deprotected, and collected. The occurrence of side reactions sets practical limits for the length of synthetic oligonucleotides (up to about 200 nucleotide residues) because the number of errors accumulates with the length of the oligonucleotide being synthesized. Products are often isolated by high-performance liquid chromatography (HPLC) to obtain the desired oligonucleotides in high purity.
Gelatine consists of partially hydrolysed collagen, a protein which is highly abundant in animal tissues such as bone and skin. Collagen is a protein made up of three strands of polypeptide chains that form in a helical structure. To make a gelatine dessert, the collagen is mixed with water and heated, disrupting the bonds that hold the three strands of polypeptides together. As the gelatine cools, these bonds try to reform in the same structure as before, but now with small bubbles of liquid in between. This gives gelatine its semisolid, gel-like texture. Because gelatine is a protein that contains both acid and base amino groups, it acts as an amphoteric molecule, displaying both acidic and basic properties. This allows it to react with different compounds, such as sugars and other food additives. These interactions give gelatine a versatile nature in the roles that it plays in different foods. It can stabilise foams in foods such as marshmallows, it can help to maintain small ice crystals in ice cream, and it can even serve as an emulsifier for foods like toffee and margarine. Although many gelatine desserts incorporate fruit, some fresh fruits contain proteolytic enzymes; these enzymes cut the gelatine molecule into peptides (protein fragments) too small to form a firm gel. The use of such fresh fruits in a gelatine recipe results in a dessert that never "sets". Specifically, pineapple contains the protease (protein cutting enzyme) bromelain, kiwifruit contains actinidin, figs contain ficain, and papaya contains papain.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.